Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...

Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.

Somewhere deep in my mind, the guilt starts to build as I know this will only make things infinitely worse in the long run.

An expert discusses how the clinical presentations of atopic dermatitis (AD) vary across different patient populations and the challenges these variations pose in diagnosis.

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

Patients with specific dermatological immune-mediated inflammatory diseases are not at increased risk of developing severe COVID-19.

Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces it has nominated and is progressing ...

The only change she mentioned was, because it was frigid outside, she and her friends were going to the mall a lot where they ...

Experts say that getting infected with measles can pose serious health risks for people that they wouldn’t face if they were vaccinated ...

While scratching an itch can worsen skin allergies, it can also improve the body’s defense mechanism against certain ...

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study ...

You start to glow when you priortise your diet. The result indicates the gut-skin axis theory. These are all the foods you ...